top of page
  • ODI Pharma

ODI Pharma AB announces the date of official launch of kandol.

ODI Pharma AB (“ODI” or the “Company”) hereby announces that kandol., the CBD skincare product line, will be officially launched as of 1st of October 2021. The products will initially be available online at to customers within the EU. In addition to the announcement, ODI also provides an update on the medical project.

ODI has been carrying out extensive research in order to implement a new business area, namely the cosmetic line that incorporates specialized, highly CBD-infused skincare products. The product line, referred to as kandol., consists of CBD-infused facial cream, facial masks and body balm with further products in development. These products contain what has been characterized as the Golden Standard of Cannabidiol by the Company, and ODI believes in having found a disrupting formula that shows outstanding effects. As of the 1st of October 2021, the product will be officially live and available on the market.

Successful pre-sales work has been done to establish the brand in the market and to make it available through multiple channels throughout Europe, online and stationary. Efforts will continue to support the rise of the brand kandol. throughout Europe in the coming months and quarters. ODI continues to have a conservative approach on deploying the budget dedicated to Project Skin.

With Project Poland, the Company is in the late stages of the application process. The discussions with authorities are going as expected and ODI is currently in the process of accommodating country specific needs for import. To date, the Company is confident that all hurdles are achievable. The Company is making headway and is optimistic to come back in the not so distant future with further updates.

For more information on ODI Pharma, please contact:

Derek Simmross, CEO, ODI Pharma AB


ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis and cosmetics products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.

210928 - Kandol going live_vf
PDF herunterladen • 735KB

0 Kommentare

Aktuelle Beiträge

Alle ansehen

ODI Pharma AB: Updated market and business overview

ODI Pharma AB (“ODI” or the “Company”) hereby present an updated overview of its market position and the latest trends observed in the cannabis industry, particularly in Europe. Progress in the cooper

ODI Pharma AB: Publication of half-year report 2023/2024

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2023. The report is available as an attached document to this press release and on the Compa


bottom of page